Search Results
Carvedilol EP IMpurity E 50 mg | Purity Not Available
TargetMol
debutylbupivacaine 200 mg | Purity Not Available
TargetMol

Debutylbupivacaine is the intermediate of ropivacaine hydrochloride and bupivacaine.
More Information Supplier Page7ACC2 1 mg | 100.00%
TargetMol

7ACC2 is a new potent MCT inhibitor with IC50 of 11 nM for [14C]-lactate influx; new antitumor treatment targeting lactate transport in Y cells.
More Information Supplier Page7ACC2 25 mg | 100.00%
TargetMol

7ACC2 is a new potent MCT inhibitor with IC50 of 11 nM for [14C]-lactate influx; new antitumor treatment targeting lactate transport in Y cells.
More Information Supplier PageRac-Belinostat 5 mg | 99.93%
TargetMol

Rac-Belinostat (PX-105684) is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
More Information Supplier PageZLN005 200 mg | Purity Not Available
TargetMol

ZLN005 is an effective and tissue-specific transcriptional activator of PGC-1α.
More Information Supplier PageZLN005 100 mg | Purity Not Available
TargetMol

ZLN005 is an effective and tissue-specific transcriptional activator of PGC-1α.
More Information Supplier PageZLN005 25 mg | Purity Not Available
TargetMol

ZLN005 is an effective and tissue-specific transcriptional activator of PGC-1α.
More Information Supplier PageMBX-2982 2 mg | 98.83%
TargetMol

MBX-2982 is a selective, orally-available GPR119 agonist, used for the treatment of diabetes.
More Information Supplier Page